论文部分内容阅读
目的探讨重组人干扰素α-2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒的临床疗效。方法选取我院妇科2012年10月至2014年10月收治的宫颈人乳头瘤病毒感染患者148例作为观察对象,将其随机分为对照组和观察组,每组74例。对照组患者采取常规药物进行治疗。观察组患者使用重组人干扰素α-2b阴道泡腾胶囊进行治疗,疗程结束1、3、6个月后,对两组患者进行检测,对比宫颈人乳头瘤病毒的负荷量。结果疗程结束第6个月后,观察组患者的HC2较第1个月下降了70.25%,对照组患者的HC2较第1个月下降了10.31%,对比两组患者结果差异显著,有统计学意义(t=7.315,P<0.05)。结论重组人干扰素α-2b阴道泡腾胶囊治疗宫颈人乳头瘤病毒,疗效显著,无不良反应,值得临床广泛推广使用。
Objective To investigate the clinical efficacy of recombinant human interferon α-2b vaginal effervescent capsules in the treatment of cervical human papillomavirus. Methods A total of 148 cases of cervical HPV infection in our hospital from October 2012 to October 2014 were selected as observation subjects and randomly divided into control group and observation group with 74 cases in each group. Patients in the control group were treated with conventional drugs. Patients in the observation group were treated with recombinant human interferon α-2b vaginal effervescent capsules. After 1, 3 and 6 months after the end of treatment, the two groups of patients were tested to compare the load of cervical HPV. Results After 6 months of treatment, HC2 in observation group dropped by 70.25% compared with that in the first month and HC1 in control group decreased by 10.31% compared with the first month. There was significant difference between the two groups Significance (t = 7.315, P <0.05). Conclusions Recombinant human interferon α-2b vaginal effervescent capsule treatment of cervical HPV, with significant effect, no adverse reactions, it is widely used in clinical practice.